In an adult with multidrug‑resistant or extensively drug‑resistant tuberculosis meningitis, what treatment regimen achieves therapeutic concentrations in the cerebrospinal fluid?

Drug-Resistant TB Meningitis: Agents with CNS Penetration

For multidrug-resistant or extensively drug-resistant tuberculous meningitis, build your regimen around fluoroquinolones (levofloxacin or moxifloxacin), linezolid, and bedaquiline—these three agents achieve therapeutic CSF concentrations and form the backbone of effective treatment. 1

Core Agents with Proven CNS Penetration

Later-Generation Fluoroquinolones (Group A Priority)

• Levofloxacin or moxifloxacin must be included as first-line agents with strong recommendation status for all MDR-TB cases, including meningitis. 1
• Moxifloxacin achieves excellent CSF penetration with concentrations of 1.52-2.43 mg/L depending on dose (400 mg vs 800 mg), with CSF/plasma ratios supporting therapeutic levels. 2
• High-dose moxifloxacin (800 mg daily) doubles CSF concentrations compared to standard 400 mg dosing without increased toxicity. 2

Linezolid (Group A Priority)

• Linezolid should be included in MDR-TB meningitis regimens with strong recommendation from WHO 2020 guidelines. 1
• Linezolid demonstrates reliable CNS penetration and has been successfully used in pre-XDR-TBM cases with documented CSF concentrations. 3
• This agent is particularly valuable given its dual bactericidal activity and proven CNS distribution. 1

Bedaquiline (Group A Priority)

• Bedaquiline should be included as a core agent with strong recommendation status for MDR-TB in adults. 1
• While bedaquiline has lower total CSF concentrations, it achieves high brain tissue concentrations and the free drug fraction may be therapeutically adequate. 4
• Bedaquiline is lipophilic and concentrates in brain tissue, making it valuable despite modest CSF levels. 4

Additional Agents to Complete the Regimen

Cycloserine/Terizidone (Group B)

• Include cycloserine when additional agents are needed to reach the minimum of 5 effective drugs during intensive phase. 1
• Cycloserine achieves excellent CSF penetration with documented therapeutic concentrations in MDR-TB meningitis cases. 3, 5
• This agent has decades of experience in CNS tuberculosis with favorable pharmacokinetic properties. 5

Clofazimine (Group B)

• Add clofazimine as a supplementary agent when constructing regimens for MDR/XDR-TBM. 1
• Clofazimine has been successfully used in pre-XDR-TBM cases, though specific CSF penetration data are limited. 3

Pyrazinamide (if susceptible)

• Include pyrazinamide when susceptibility is documented or highly likely, as it achieves excellent CSF concentrations equal to plasma levels. 1
• Pyrazinamide remains one of the best CNS-penetrating anti-TB drugs and should be retained when the isolate is susceptible. 1

Ethambutol (Group C - last resort)

• Add ethambutol only when other more effective drugs cannot be assembled to reach 5 total agents. 1
• Ethambutol has poor CSF penetration and should be avoided if better alternatives exist. 1

Agents with Limited or Inadequate CNS Penetration

Delamanid (Conditional consideration)

• Delamanid may be included in patients ≥3 years old when additional agents are needed, though evidence is limited. 1
• Delamanid achieves low total CSF concentrations (mean 48 ng/mL in humans, 0.47-1.26 ng/mL in rabbits) but high brain tissue concentrations (5-fold higher than plasma). 4
• The free CSF/plasma ratio exceeds 1.0, suggesting adequate free drug despite low total levels, and clinical improvement has been documented in XDR-TBM patients. 4

Injectable Agents (Generally avoid)

• Amikacin or streptomycin may be included only when susceptibility is confirmed and oral alternatives are insufficient. 1
• Do NOT use kanamycin or capreomycin as these are specifically recommended against in current guidelines. 1
• Injectable aminoglycosides have poor CSF penetration and are being phased out of MDR-TB treatment. 1

Carbapenems with Clavulanate

• Consider adding a carbapenem (with amoxicillin-clavulanate) when additional bactericidal activity is needed in severe XDR-TBM cases. 1
• Limited data exist on carbapenem CNS penetration in TBM, but they may contribute to regimen efficacy. 1

Regimen Construction Algorithm

Intensive Phase (5-7 months after culture conversion)

1. Start with all three Group A agents: fluoroquinolone + linezolid + bedaquiline 1
2. Add at least one Group B agent: cycloserine or clofazimine 1
3. Include pyrazinamide if susceptible 1
4. Ensure minimum of 5 effective drugs total 1

Continuation Phase (Total 15-24 months after culture conversion)

• Continue at least 4 effective drugs after stopping bedaquiline (if stopped). 1
• For pre-XDR and XDR-TBM, treat for 15-24 months after culture conversion to ensure adequate sterilization. 1

Critical Pitfalls to Avoid

• Never rely on ethambutol as a core agent in CNS tuberculosis due to poor penetration—use it only as a fifth drug when no alternatives exist. 1
• Avoid kanamycin and capreomycin entirely as they are specifically contraindicated in current MDR-TB guidelines. 1
• Do not assume adequate CSF penetration from pulmonary TB data—CNS pharmacokinetics differ substantially and require specific consideration. 6, 7
• Recognize that standard rifampin dosing (10 mg/kg) achieves subtherapeutic CSF levels when MIC ≥0.5 mg/L, though this is less relevant in rifampin-resistant cases. 6
• Monitor for linezolid toxicity (myelosuppression, peripheral neuropathy) as prolonged use is required in MDR-TBM. 1

Emerging Considerations

• High-dose rifampin (13 mg/kg IV) triples CSF concentrations and may reduce 6-month mortality (35% vs 65%) in drug-susceptible TBM, though this is not applicable to rifampin-resistant cases. 2
• Therapeutic drug monitoring should be considered when available to optimize second-line agent dosing in CNS disease. 3, 5
• Novel regimens containing bedaquiline, pretomanid, and linezolid (BPaL) show promise but lack specific TBM outcome data. 8